Premenopausal

Questions discussed in this category

In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?

1 Answer available

Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?

Did the ASCO 2024 presentation from RxPONDER change your practice?

1 Answer available

Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?

3 Answers available

Papers discussed in this category

Lancet Oncol., 2018 Nov 06

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Lancet (London, England), 2014-06-21

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

The New England journal of medicine, 2024 Mar 21

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Related Topics